Piramal Pharma Limited
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Peter Daniel DeYoung
- Full Time Employees
- 10,440
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Ananta Building Mumbai MH India 400 070
- IPO Date
- Oct 19, 2022
- Website
- piramalpharma.com
- Similar Companies
- Business
- Piramal Pharma Limited functions as a global pharmaceutical company, offering a comprehensive array of differentiated products and specialized services. The enterprise operates through three principal segments: Piramal Pharma Solutions, an integrated contract development and manufacturing organization providing end-to-end solutions, including complex active pharmaceutical ingredients and sterile injectables; Piramal Critical Care, delivering complex hospital generics for critical treatment areas; and its India Consumer Healthcare division, which markets a variety of over-the-counter wellness products. Incorporated on March 4, 2020, and based in Mumbai, India, the company maintains a global footprint with numerous manufacturing facilities and a distribution network reaching over 100 countries. Piramal Pharma Limited became a publicly listed entity in October 2022, following its demerger from Piramal Enterprises Limited, and is part of the wider Piramal Group.
Company News
/C O R R E C T I O N -- Piramal Pharma Solutions/
/C O R R E C T I O N -- Piramal Pharma Solutions/
Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site
Piramal Pharma Limited finalise l'acquisition d'une participation majoritaire dans Yapan Bio Private Limited
Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
Piramal Pharma Solutions erweitert Peptid-API-Anlage um moderne Sprühtrocknungsanlage
Piramal Pharma Solutions agrandit son site de production d'API peptidiques avec l'ajout d'une unité de séchage par atomisation de pointe
Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying Suite
Piramal Pharma Limited annonce ses résultats pour le T1 2027
Le rapport annuel de Piramal Pharma pour l'exercice 2026 souligne l'envergure mondiale de la société, sa croissance axée sur l'innovation et ses avancées majeures en matière de développement durable
Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
Piramal Pharma Solutions enthüllt hochmoderne Payload-Linker-Suite in seinem Werk in Riverview, Michigan
Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
Piramal Pharma Solutions et Ajinomoto Bio-Pharma Services collaborent pour soutenir le développement et la fabrication de CAM
Piramal Pharma Solutions commémore le 20e anniversaire de son site de Morpeth en achetant une presse à comprimés Korsch X3
Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
Werk von Piramal Pharma Solutions im schottischen Grangemouth liefert erfolgreich die 1.500ste ADC-Charge aus
L'usine de Piramal Pharma Solutions à Grangemouth, au Royaume-Uni, livre avec succès le 1 500ᵉ lot d'ADC